Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Bleakley Financial Group LLC

Bleakley Financial Group LLC grew its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 2.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,678 shares of the company’s stock after purchasing an additional 338 shares during the period. Bleakley Financial Group LLC’s holdings in Ionis Pharmaceuticals were worth $668,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Teachers Retirement System of The State of Kentucky increased its position in shares of Ionis Pharmaceuticals by 70.6% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 24,083 shares of the company’s stock worth $1,044,000 after acquiring an additional 9,965 shares during the period. Entropy Technologies LP acquired a new position in Ionis Pharmaceuticals during the 1st quarter worth approximately $630,000. Edgestream Partners L.P. purchased a new stake in shares of Ionis Pharmaceuticals in the 1st quarter valued at approximately $765,000. Blair William & Co. IL raised its holdings in shares of Ionis Pharmaceuticals by 67.4% in the 1st quarter. Blair William & Co. IL now owns 27,838 shares of the company’s stock valued at $1,207,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ionis Pharmaceuticals during the first quarter worth $613,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

IONS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, August 2nd. Barclays boosted their price target on shares of Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Jefferies Financial Group began coverage on Ionis Pharmaceuticals in a report on Tuesday, July 16th. They set a “buy” rating and a $75.00 price objective on the stock. Finally, Leerink Partnrs raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $60.28.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Richard S. Geary sold 2,430 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $48.00, for a total transaction of $116,640.00. Following the sale, the executive vice president now directly owns 85,508 shares in the company, valued at approximately $4,104,384. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 2,803 shares of company stock worth $134,402 in the last quarter. Company insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $39.00 on Tuesday. The company’s fifty day moving average is $43.07 and its two-hundred day moving average is $43.21. The company has a debt-to-equity ratio of 4.67, a quick ratio of 7.51 and a current ratio of 7.61. The firm has a market capitalization of $5.69 billion, a P/E ratio of -14.61 and a beta of 0.38. Ionis Pharmaceuticals, Inc. has a one year low of $35.95 and a one year high of $54.44.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative net margin of 44.90% and a negative return on equity of 115.66%. The firm had revenue of $225.00 million for the quarter, compared to the consensus estimate of $152.35 million. During the same quarter in the previous year, the firm earned $0.60 earnings per share. The firm’s revenue was up 19.7% on a year-over-year basis. Analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.68 EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.